Our Parkinson's Place: Medical Affairs Reputations (EU5) [Parkinson's Disease]

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

Tuesday, November 28, 2017

Medical Affairs Reputations (EU5) [Parkinson's Disease]

Nov. 28, 2017

LONDON, /PRNewswire/ -- How well does your Parkinson's Disease medical affairs team performance compare with the rest?

According to this latest survey of 150 neurologists across the EU5 (UK, France, Germany, Italy and Spain) the performance of Parkinson's Disease medical affairs teams still has a way to go in some key areas. Find out what physicians think is done well; what they want to see more of; and why some are dissatisfied.

Use Medical Affairs Reputations: Parkinson's Disease 2017 (EU5) to discover how your team can better meet the high expectations of physicians at the frontline.

This report compares the current activities of medical affairs teams for the 9 leading treatments for Parkinson's Disease from AbbVie, Britannia, GSK, Lundbeck, Meda Pharma, Novartis, Teva, UCB and Zambon. It shows:

• How physicians rate each team overall, and for 12 key medical affairs services.

• What is most important to physicians, plus what can be done better.

• How, and how often physicians want to meet with your team.

It's time to find out exactly how well your medical affairs team is performing against fierce competition – and establish an action plan to gain competitive advantage.

Top Takeaways

• One clear winner, but plenty to play for. Four teams visit over two thirds of physicians, with one a full 10 points clear in the lead; is this your team? If not, what can you do to gain ground?

• Building confidence. How much do European physicians rely on medical affairs to answer questions about off-label usage? What are they spending more time talking about to medical affairs professionals than ever before?

• How are the new kids on the block faring against the old guard? New brands on the market are benchmarked against established therapies, but how are they doing? Is it a case of not enough time on the market, or are they proactively shaping physician sentiment?

• Are patients the main focus, or is it something else? How much do European physicians rely on medical affairs to help them improve patient access, education and outcomes? And are they spending more or less time doing this than before?

• Information or attitude? When it comes to what physicians recommend in terms of key areas for improvement, is it information, attitude or something else? Could addressing these tip the balance?

Insight into Medical affairs teams for these Parkinson's Disease treatments

• Apokinon (apomorphine SC; Britannia)

• Azilect (rasagiline; Teva/Lundbeck)

• Comtan (entacapone; Novartis)

• Dostinex (cabergoline; Pfizer)

• Duodopa (levodopa/carbidopa intraduodenal; AbbVie)

• Neupro (rotigotine; UCB)

• Requip (ropinirole; GSK)

• Tasmar (tolcapone; Meda Pharma)

• Xadago (safinamide; Zambon)

A Competitive View of Your Medical Affairs Team

Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of medical affairs teams for 9 leading Parkinson's Disease brands—answering important questions like:

What do physicians need?

• How, and how often are they using your medical affairs team?

• What services do they consider most important?

• How often should you contact them? What channels are best?

Does your medical affairs team deliver?

• How memorable are your team's interactions with doctors?

• How do doctors rank your team for performance and satisfaction in 12 key areas?

• How does your team compare to the competition—in each area, and overall?

What needs improvement?

• Are you delivering the services that are most important to doctors?

• Where do you need to improve?

• How can your team enhance its services?